Survival of patients with mucosal melanoma in Cali, Colombia: a retrospective cohort study.

Autor: García AM; Hematology and Clinical Oncology Service, Department of Internal Medicine, Fundación Valle del Lili, Cra. 98 Nro.18 -49, 760032, Cali, Colombia., Parra-Lara LG; Centro de Investigaciones Clínicas (CIC), Fundación Valle del Lili, Cali, Colombia.; Facultad de Ciencias de La Salud, Universidad Icesi, Cali, Colombia., Mendoza-Urbano DM; Centro de Investigaciones Clínicas (CIC), Fundación Valle del Lili, Cali, Colombia., Bravo JC; Departament of Pathology and Clinical Laboratory, Fundación Valle del Lili, Cali, Colombia., Zambrano Harvey Á; Hematology and Clinical Oncology Service, Department of Internal Medicine, Fundación Valle del Lili, Cra. 98 Nro.18 -49, 760032, Cali, Colombia. angela.zambrano@fvl.org.co.; Facultad de Ciencias de La Salud, Universidad Icesi, Cali, Colombia. angela.zambrano@fvl.org.co.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2024 Jul 23; Vol. 24 (1), pp. 886. Date of Electronic Publication: 2024 Jul 23.
DOI: 10.1186/s12885-024-12371-x
Abstrakt: Background: Mucosa melanoma is a rare condition with aggressive behavior and a less favorable prognosis compared to cutaneous melanoma. The objective of this study was to estimate the overall survival and clinical outcomes of patients diagnosed with mucosal melanoma in a Colombian hospital.
Methods: A retrospective cohort study was conducted at Fundación Valle del Lili, a single center located in Cali, Colombia. Patients aged ≥ 18 years, both sexes, diagnosed with mucosal melanoma by histopathology study were included between 2010-2019. Patients who received extra-institutional treatment or whose vital status was unknown during follow-up were excluded. Demographic, clinical and laboratory data were obtained from medical records and laboratory and pathology databases. A descriptive analysis was performed. Survival analysis was conducted using the Kaplan-Meier method.
Results: A total of 23 patients were included. Median age was 63 years old (IQR: 57-68) and 52.2% were woman. Clinical stage was 34.8% early, 26.1% locally advanced and 39.1% metastatic. The main primary locations were nasopharynx (30.4%), genitals (26.1%), rectum (21.7%), oral cavity (13%) and paranasal sinuses (8.7%). The majority received surgery (30.4%) and immunotherapy (26.1%) as first line treatment. Overall survival at one year was 80.8%, at three years 44.3%, and at five years 36.9%.
Conclusion: Mucosal melanoma is a rare, aggressive disease with adverse oncological outcomes due to late diagnosis and limited treatment options. This study provides real-world data in a single-center of Colombia.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje